Entrada Therapeutics (TRDA) Assets Average (2021 - 2026)

Entrada Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $356.4 million for Q1 2026.

• On a quarterly basis, Assets Average fell 29.61% year-over-year to $356.4 million in Q1 2026; TTM through Mar 2026 was $356.4 million, a 29.61% decrease from a year earlier, with the FY2025 full-year figure at $451.8 million, down 9.22% from the prior year.
• Assets Average fell to $356.4 million in Q1 2026 per TRDA's latest filing, from $395.1 million in the prior quarter.
• Across five years, Assets Average topped out at $568.3 million in Q3 2024 and bottomed at $263.3 million in Q4 2022.
• The 5-year median for Assets Average is $467.6 million (2025), against an average of $428.4 million.
• Across the five-year window, Assets Average surged 81.23% in 2023 and slipped 29.61% in 2026, its largest moves.
• Year by year, Assets Average stood at $263.3 million in 2022, then soared by 81.23% to $477.1 million in 2023, then climbed by 13.28% to $540.5 million in 2024, then fell by 26.89% to $395.1 million in 2025, then slipped by 9.79% to $356.4 million in 2026.
• Per Business Quant, the three latest TRDA Assets Average figures stand at $356.4 million (Q1 2026), $395.1 million (Q4 2025), and $430.8 million (Q3 2025).